Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases: An overview

Pharmaceutical Research

Volumn 28, Issue 2, 2011, Pages 413-416

  Marrero, Mario B ^a   Bencherif, Merouane ^b   Lippiello, Patrick M ^b   Lucas, Rudolf ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b TARGACEPT INC   (United States)

Author keywords

alpha7 nicotinic acetylcholine receptor agonists; cholinergic anti inflammatory pathway; inflammation; Jak STAT pathway

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA BUNGAROTOXIN; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR AGONIST; CAP 55; CYTOKINE; JANUS KINASE 2; METHYLLYCACONITINE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINE; NICOTINIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; TC 7020; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTERY WALL; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENDOTHELIUM CELL; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; MACROPHAGE; NONHUMAN; NOTE; PRIORITY JOURNAL; SEPSIS; STIMULUS RESPONSE; VEIN WALL;

ANIMALS; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERLEUKINS; MACROPHAGES; MICE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952487267     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0283-7     Document Type: Note

References (10)

1. Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res. 2009;1256:1-7.
2. Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM. Longlasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci. 2005;26:352-60. (Pubitemid 40848496)
3. Marrero MB, Lucas R, Salet C, Hauser TA, Mazurov A, Lippiello PM, et al. An alpha7 nicotinic acetylcholine receptorselective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J Pharmacol Exp Ther. 2010;332: 173-80.
4. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med. 2005;201:1113-23. (Pubitemid 40524679)
5. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921): 384-8. (Pubitemid 36157937)
6. Shaw S, Bencherif M, Marrero MB. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J Biol Chem. 2002;277:44920-4. (Pubitemid 36159088)
7. Shaw S, Bencherif M, Marrero MB. Angiotensin II blocks nicotine-mediated neuroprotection against beta-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1. J Neurosci. 2003;23:11224-8.
8. Takahashi HK, Liu K, Wake H, Mori S, Zhang J, Liu R, et al. Effect of nicotine on advanced glycation end product-induced immune response in human monocytes. J Pharmacol Exp Ther. 2010;332(3):1013-21.
9. Altavilla D, Guarini S, Bitto A, Mioni AC, Giuliani D, Bigiani A, et al. Activation of the cholinergic anti-inflammatory pathway reduces NF-kappaB activation, blunts TNF-alpha production, and protects againts splanchic artery occlusion shock. Shock. 2006;25(5):500-6.
10. Su X, Matthay MA, Malik AB. Requisite role of the cholinergic alpha7 nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced acute lung inflammatory injury. J Immunol. 2010;184(1):401-10.